A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer

NCT02898077 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

440

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastroesophageal Junction Adenocarcinoma
Gastric Adenocarcinoma

Interventions

DRUG: Ramucirumab
DRUG: Paclitaxel
DRUG: Placebo

Sponsor

Eli Lilly and Company